Journal ArticleDOI
Potential of long non-coding RNAs in cancer patients: From biomarkers to therapeutic targets
TLDR
LncRNAs are emerging as convenient and minimally invasive diagnostic/prognostic markers, and also as therapeutic target for the selective killing of cancer cells in patients.Abstract:
Because of high specificity and easy detection in the tissues, serum, plasma, urine and saliva, interest in exploring the potential of long non-coding RNAs (lncRNAs) in cancer patients continues to increase. LncRNAs have shown potential as a biomarker in the diagnosis and prognosis of bladder cancer, prostate cancer, gastric cancer, pancreatic cancer, breast cancer and many other cancer types. Some lncRNAs have also been used as adjunct to improve the specificity and sensitivity of existing biomarkers. The molecular tools such as RNA-seq, RNA-FISH, ic-SHAPE and quantitative real-time PCR have been used for examining the lncRNAs' potential. Some lncRNAs such as PCA3 is now routinely used in the clinic for the diagnosis of prostate cancer. Single nucleotide polymorphisms (SNPs) in lncRNAs can also be used as a predictor of cancer risk. Although ongoing studies continue to unravel the underlying mechanism, some lncRNAs have been used as therapeutic targets for the selective killing of cancer cells in patients. Thus lncRNAs are emerging as convenient and minimally invasive diagnostic/prognostic markers, and also as therapeutic target. Companies such as the Curna Inc., MiNA Therapeutics Ltd. and RaNA Therapeutics Inc. have been taking steps to develop lncRNA based strategies against cancer. In this review, we discuss the potential of lncRNAs as biomarkers and therapeutic targets in cancer patients.read more
Citations
More filters
Journal ArticleDOI
Biomarkers of gastric cancer: Current topics and future perspective.
Tasuku Matsuoka,Masakazu Yashiro +1 more
TL;DR: The current status and approaches in GC biomarker are summarized, which could be potentially used for early diagnosis, accurate prediction of therapeutic approaches and the future perspective based on the molecular classification and profiling is discussed.
Journal ArticleDOI
LncRNA MT1JP functions as a ceRNA in regulating FBXW7 through competitively binding to miR-92a-3p in gastric cancer
Gang Zhang,Shuwei Li,Jiafei Lu,Yuqiu Ge,Qiaoyan Wang,Gaoxiang Ma,Qinghong Zhao,Dongdong Wu,Weida Gong,Mulong Du,Haiyan Chu,Meilin Wang,Aihua Zhang,Zhengdong Zhang +13 more
TL;DR: MT1JP, a down-regulated lncRNA in GC, was associated with malignant tumor phenotypes and survival of GC, and it is suggested that MT1JP may act as a potential therapeutic target and prognosis biomarker for GC.
Journal ArticleDOI
Long non-coding RNAs are emerging targets of phytochemicals for cancer and other chronic diseases.
Shruti Mishra,Sumit Singh Verma,Vipin Rai,Nikee Awasthee,Srinivas Chava,Kam M. Hui,Alan Prem Kumar,Kishore B. Challagundla,Gautam Sethi,Subash C. Gupta +9 more
TL;DR: How the modulation of lncRNAs by phytochemicals produce therapeutic effects on cancer and other chronic diseases is discussed in this review.
Journal ArticleDOI
Drugging the lncRNA MALAT1 via LNA gapmeR ASO inhibits gene expression of proteasome subunits and triggers anti-multiple myeloma activity.
Nicola Amodio,Maria Angelica Stamato,Giada Juli,Eugenio Morelli,Mariateresa Fulciniti,Martina Manzoni,Martina Manzoni,Elisa Taiana,Elisa Taiana,Luca Agnelli,Luca Agnelli,Maria Eugenia Gallo Cantafio,Enrica Romeo,Lavinia Raimondi,Daniele Caracciolo,Valeria Zuccalà,Marco Rossi,Antonino Neri,Antonino Neri,Nikhil C. Munshi,Nikhil C. Munshi,Pierosandro Tagliaferri,Pierfrancesco Tassone,Pierfrancesco Tassone +23 more
TL;DR: A crucial role of MALAT1 in the regulation of the proteasome machinery is demonstrated, and proof-of-concept that its targeting is a novel powerful option for the treatment of MM is provided.
Journal ArticleDOI
Long Non-coding RNA NEAT1: A Novel Target for Diagnosis and Therapy in Human Tumors.
Peixin Dong,Ying Xiong,Junming Yue,Sharon J.B. Hanley,Noriko Kobayashi,Yukiharu Todo,Hidemichi Watari +6 more
TL;DR: The latest insights into the expression pattern, biological roles and mechanisms underlying the function and regulation of NEAT1 in tumors are highlighted, and its clinical implication as a new diagnostic biomarker and an attractive therapeutic target for cancers is focused on.
References
More filters
Journal ArticleDOI
High expression of AFAP1-AS1 is associated with poor survival and short-term recurrence in pancreatic ductal adenocarcinoma
Yibiao Ye,Jie Chen,Yu Zhou,Zhiqiang Fu,Quanbo Zhou,Yingxue Wang,Wenchao Gao,Shangyou Zheng,Xiaohui Zhao,Tao Chen,Rufu Chen +10 more
TL;DR: AFAP1-AS1 is a potential novel prognostic marker to predict the clinical outcome of PDAC patients after surgery and may be a rational target for therapy.
Journal ArticleDOI
DrugTargetSeqR: a genomics- and CRISPR-Cas9–based method to analyze drug targets
TL;DR: An approach, named DrugTargetSeqR, is developed, which combines high-throughput sequencing, computational mutation discovery and CRISPR/Cas9-based genome editing to identify the physiological targets of drugs and bioactive small molecules and uncover genetic and epigenetic mechanisms likely to cause drug resistance in human cancer cells.
Journal ArticleDOI
The CASC15 Long Intergenic Noncoding RNA Locus Is Involved in Melanoma Progression and Phenotype Switching
Laurent Lessard,Michelle Liu,Diego M. Marzese,Hongwei Wang,Kelly Chong,Neal P. Kawas,Nicholas C. Donovan,Eiji Kiyohara,Sandy C. Hsu,Nellie Nelson,Sivan Izraely,Orit Sagi-Assif,Isaac P. Witz,Xiao-Jun Ma,Yuling Luo,Dave S.B. Hoon +15 more
TL;DR: In clinical specimens, CASC15 levels increased during melanoma progression and were independent predictors of disease recurrence in a cohort of 141 patients with AJCC stage III lymph node metastasis, and siRNA knockdown experiments revealed that CASC 15 regulates melanoma cell phenotype switching between proliferative and invasive states.
Journal ArticleDOI
Upregulation of the long noncoding RNA PCAT-1 correlates with advanced clinical stage and poor prognosis in esophageal squamous carcinoma
Shi Weihong,Qing-Quan Wu,Li Suqing,Yang Tongxin,Liu Zihao,Tong Yusuo,Lei Tuo,Shan Wang,Xiu-Feng Cao +8 more
TL;DR: High expression of PCAT-1 was specifically correlated with invasion of cancer tissues, metastasis of lymph node, and advanced tumor stage of ESCC, indicating a potential diagnostic target in ESCC patients.
Journal ArticleDOI
DNA Based Therapy with Diphtheria Toxin-A BC-819: A Phase 2b Marker Lesion Trial in Patients with Intermediate Risk Nonmuscle Invasive Bladder Cancer
Ofer N. Gofrit,Shalva Benjamin,Sarel Halachmi,Ilan Leibovitch,Zohar A. Dotan,Donald L. Lamm,Nahum Ehrlich,Vladimir Yutkin,Monique Ben-Am,Abraham Hochberg +9 more
TL;DR: BC-819 prevented new tumor growth in two-thirds of the patients and ablated a third of the marker lesions make BC- 819 a potential medication for bladder cancer.